TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06094257

Intervention type: DIAGNOSTIC_TEST
Intervention: Sensory testing
Description: Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)

Intervention type: DIAGNOSTIC_TEST
Intervention: Sensory testing
Description: Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)

Intervention type: DIAGNOSTIC_TEST
Intervention: Sensory testing
Description: Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)

Intervention type: DIAGNOSTIC_TEST
Intervention: Sensory testing
Description: Quantitative sensory testing (QST) will be performed. QST was developed to standardize the noninvasive assessment of the somatosensory nervous system and quantify functioning of all aspects of sensation (light touch, pressure, warm, cold, pain, vibration): 1. Thermal detection (Medoc TSA system): Cold detection threshold B) Warm detection threshold C) Heat pain threshold 2. Mechanical detection threshold (MRC Opti Hair von Frey Filaments) 3. Two-point discrimination (MRC Opti Hair von Frey Filaments) 4. Mechanical pain threshold (MRC Pinprick Stimulator) 5. Pressure pain threshold (Medoc Pressure algometer) 6. Tinel sign on physical exam 7. Vibration (tuning fork)
Study: NCT06268340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECochG monitored CI surgery incl. corrective action guide
Description: Interventional surgery with surgeon having access to intra-operative ECochG monitoring feedback to deploy ECochG based corrective action guide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine CI surgery without ECochG monitoring
Description: Routine CI surgery with access to ECochG monitoring by surgeon
Study: NCT04984369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: HLX208 450mg bid po OR 600mg bid po OR 900mg bid po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: HLX208 450mg bid po OR 600mg bid po OR 900mg bid po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: HLX208 450mg bid po OR 600mg bid po OR 900mg bid po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Injection [Erbitux]
Description: Cetuximab 500 mg/m2 IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Injection [Erbitux]
Description: Cetuximab 500 mg/m2 IV Q2W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Injection [Erbitux]
Description: Cetuximab 500 mg/m2 IV Q2W
Study: NCT05402969

Intervention type: PROCEDURE
Intervention: Transimedance Matrix measurements
Description: TIM measurements are based on cochlear implant back-telemetry function. Each electrode contact is stimulated in monopolar mode. Transimpedance is represented by the ratio between the voltage measured at each recording electrode and the current injected at the stimulation contact. The result of the measurements is a matrix of 21x21 transimpedances. Stimulation current cannot be perceived by a patient thus making TIM measurements a non-invasive and painless procedure. The test duration is only 2-3 minutes

Intervention type: PROCEDURE
Intervention: Transimedance Matrix measurements
Description: TIM measurements are based on cochlear implant back-telemetry function. Each electrode contact is stimulated in monopolar mode. Transimpedance is represented by the ratio between the voltage measured at each recording electrode and the current injected at the stimulation contact. The result of the measurements is a matrix of 21x21 transimpedances. Stimulation current cannot be perceived by a patient thus making TIM measurements a non-invasive and painless procedure. The test duration is only 2-3 minutes

Intervention type: PROCEDURE
Intervention: Depth sounding and spectroscopy
Description: Depth sounding and spectroscopy are based on the matrixes obtained after TIM imaging. Deep sounding measures the capacitances throughout the electrode array whereas spectroscopy determines the phase of every transimpedance value. These tests take 10 to 15 minutes together. The stimulation intensity used by depth sounding technique can be perceived by a patient. If it is considered as unpleasant, the test will be stopped.

Intervention type: PROCEDURE
Intervention: Depth sounding and spectroscopy
Description: Depth sounding and spectroscopy are based on the matrixes obtained after TIM imaging. Deep sounding measures the capacitances throughout the electrode array whereas spectroscopy determines the phase of every transimpedance value. These tests take 10 to 15 minutes together. The stimulation intensity used by depth sounding technique can be perceived by a patient. If it is considered as unpleasant, the test will be stopped.

Intervention type: PROCEDURE
Intervention: Cone Beam Computer Tomography
Description: CBCT is a routine postoperative assessment after CI, non-invasive and painless for patients.

Intervention type: PROCEDURE
Intervention: Cone Beam Computer Tomography
Description: CBCT is a routine postoperative assessment after CI, non-invasive and painless for patients.
Study: NCT05241535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: oral
Study: NCT04439968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical algorithm
Description: In order to maintain cerebral saturations within targeted range, subjects in the targeted Csat arm will undergo clinical interventions based on clinical algorithm. Interventions may include administration of inotropes, fluid resuscitation, transfusion of blood products, and/or adjustment to respiratory support.
Study: NCT05241535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral
Study: NCT06464367

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: synthetic THC 2.5 mg (oral)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: synthetic THC 2.5 mg (oral)
Study: NCT05241535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT05159310

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cast vs Splint
Description: Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cast vs Splint
Description: Patients presenting with DRF will be screened by the attending consultant. The temporary backslab will be removed, X-rays will be obtained, and the attending consultant will discuss the treatment options. Patients who are planned for non-operative treatment and meet the inclusion criteria will be eligible for the study. The purpose and details of the study will be explained and informed consent will then be taken by the research coordinator (RC). The participants will then be randomized (using a block-randomization method) to either treatment by splint or cast.
Study: NCT04560764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~1. Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~2. Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~3. Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~4. Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality
Description: Participants in both groups will attend 10 sessions of approximately 30 minutes each three times a week. Each session contemplates the execution of a single repetition of two minutes of each of the four exercises.~There are four exercises:~1. Reaching: the participant is requested to reach a target in front of him with the paretic hand; the target will appear in a different place every time;~2. Reaching and grasping: the participant is requested to grab a wooden cube with the paretic hand and place it into a bowl positioned in front of him; the cube will appear in a different place every time;~3. Goalkeeper: the participant is requested to block a ball coming towards him with the paretic hand; the ball will appear in a different place every time;~4. Occupational task: the participant is requested to grab four cans, one at time, with the paretic hand and place them on four targets placed on a hemispherical arch.~Each exercise provides six levels of increasing difficulty.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Action Observation Therapy
Description: Before the execution of the exercises described in the intervention Virtual Reality, the participants in the experimental group will see a video demonstrating the same exercise (according to the level of difficulty selected) he will be later asked to perform for two minutes.
Study: NCT04259424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise + Duck Duck Punch
Description: Subjects will perform 15 minutes of aerobic exercise on a recumbent stationary cycle. On each session the target intensity of aerobic exercise will be 70% heart rate reserve.~Following a 10-minute rest break subjects will perform 200 repetitions on an upper extremity rehabilitation game called Duck Duck Punch (DDP). Duck Duck Punch is an interactive game with an old school carnival theme. DDP is unique as it uses Microsoft Kinect skeletal tracking technology to assess movement performance. The participant sits in front of the Microsoft Kinect and controls a virtual arm with his/her physical arm; reaching forward to punch virtual ducks. A therapist will oversee the subject's safety and progress during DDP. DDP will be dosed based on the number of repetitions performed. A repetition is recorded when the player moves his/her arm so that the avatar leaves a start position. The goal dose for subjects will be 200 repetitions per DDP session.
Study: NCT04614233

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RiduZone (90% OEA)
Description: Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA ) daily for 16 months
Study: NCT05628038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Toripalimab): 240mg q3w or 160mg q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 400 mg/m2 (bolus) and 2400 mg/m2 (continuous infusion for 48hr)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: 400 mg/m2 q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m² q3w or 85 mg/m² q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m² q2w and 200 mg/m² q3w
Study: NCT04614233

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months. Placebo capsules will consist of 180mg of hypromellose.
Study: NCT06399289

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)
Description: Lyophilized powder for solution for intravenous injection
Study: NCT06458920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social regulation
Description: Participants will regulate emotion with the help of a friend

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive regulation
Description: Participants will regulate emotion on their own
Study: NCT05807659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fractionated busulfan-based conditioning regimen
Description: Drug: Chidamide 30 mg oral twice weekly for 2 weeks Drug: Fludarabine 35 mg/m2 intravenously daily for 5 days in the 2nd week Drug: Cytarabine~1 g/m2 intravenously for 5 days in the 2nd week Drug: Busulfan 3.2 mg/kg intravenously daily for 2 days in the 1st week, 1.6 mg/kg intravenously daily for 4 days in the 2nd week Procedure/Surgery: allogeneic hematopoietic stem cell transplantation
Study: NCT06460558

Intervention type: OTHER
Intervention: Type 1 diabetes with insulin infusion system
Description: No intervention
Study: NCT05628038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: 2 mg/m² q2w and 3 mg/m² q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 400 mg/m² q2w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg q2w or 7.5mg/kg q3w

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 25-40Gy/5Fx irradiation or 15-30Gy/5Fx reirradiation (pelvic radiation history) for pelvic recurrence tumor.~35-60Gy/5-8Fx irradiation for distance metastasis tumor.
Study: NCT06239194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX2001
Description: MDX2001 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX2001
Description: MDX2001 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX2001
Description: MDX2001 intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDX2001
Description: MDX2001 intravenous infusion
Study: NCT06138262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health promotion of education pre-conception nutritional preparation
Description: Providing education on pregnancy nutritional preparation during the preconception period 3 months before the wedding
Study: NCT05770271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The novel electrolyzed water spray
Description: Study staff will use the novel electrolyzed water spray device and spray for approximately 5 minutes on the participant's diseased area until half a bottle (200ml) of water is used. The patients use electrolyzed water to treat the diseased area, two times a day, for 10 days. The trial consists of 10 study visits (day 1-day 10). The relief of mild senile groin eczema, neurodermatitis and psoriasis evaluation and adverse event assessments will be performed at each visit. Safety analysis will be assessed based on the reports of adverse events during the study.
Study: NCT05343039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Transcutaneous Nerve Stimulation (tVNS)
Description: Participants will engage in 25-minute tVNS sessions every day for 30 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Intervention
Description: Participants will not receive any intervention.
Study: NCT05778435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wireless fetal monitoring system
Description: The wireless fetal monitoring system shortens the period of labor by enabling the woman to be more mobile during the intrapartum period.
Study: NCT06525402

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Bicarbonate Group (Usual care)
Description: In the clinic where the research was conducted, a guideline is routinely applied for the care of oral mucositis in line with the stages of oral mucositis. Sodium bicarbonate is used in line with this guideline. The first group, the control group, will receive routine oral care in the clinic with sodium bicarbonate. Oral care will be applied 4 times a day for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Group
Description: The second group, the experimental group, will first receive oral care routinely applied in the clinic. Then, oral care will be given in the form of 5 ml mouthwash with saline. Oral care will be applied 4 times a day for 14 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Mulberry Syrup Group
Description: The third group, the experimental group, will first receive oral care routinely applied in the clinic. Then black mulberry syrup will be applied. Then, oral care will be given in the form of 5 ml mouthwash with black mulberry syrup. Oral care will be applied 4 times a day for 14 days.
Study: NCT05936606

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel monotherapy
Description: Patients will receive clopidogrel monotherapy (75 mg qd) for 24 months after randomization, irrespective of PRU value or bleeding risk.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored anti-platelet therapy
Description: In the tailored therapy arm, non-HPR (PRU\<208) patients will continue clopidogrel monotherapy until the end of the study at 24 months from randomization, while HPR (PRU≥208) patients will receive dual anti-platelet therapy according to the clinical diagnosis at the time of drug-eluting stent placement: High-risk patients with prior myocardial infarction will receive ticagrelor 60 mg twice daily wiht aspirin 100 mg daily, while the remainder will receive clopidogrel 75 mg daily with aspirin 100 mg daily. For HBR patietns, early cessation of dual antiplatelet therapy or aspirin monotherapy could be considered at the investigator's discretion.
Study: NCT05397912

Intervention type: DIAGNOSTIC_TEST
Intervention: Uterine Elastography
Description: Shear wave elastography data will be obtained at the transvaginal ultrasound visit the day prior to frozen embryo transfer
Study: NCT03865615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal oxytocin 40IU/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal oxytocin 40IU/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06117501

Intervention type: DEVICE
Group type: OTHER
Intervention: Axoguard HA+ Nerve Protector™
Description: Axoguard HA+ Nerve Protector™ is a surgical implant that provides non-constricting protection for non-transected peripheral nerve injuries where there is no gap. Axoguard HA+ Nerve Protector™ is designed to be an interface between the nerve and the surrounding tissue.
Study: NCT06228352

Intervention type: OTHER
Intervention: Feces collection
Description: A single stool sample will be taken (a specific kit will be given to the patient for this) during a consultation for follow-up or hospitalization.~Stool samples will be used to study the composition of the intestinal microbiota and to measure faecal biomarkers.

Intervention type: OTHER
Intervention: Feces collection
Description: A single stool sample will be taken (a specific kit will be given to the patient for this) during a consultation for follow-up or hospitalization.~Stool samples will be used to study the composition of the intestinal microbiota and to measure faecal biomarkers.

Intervention type: OTHER
Intervention: Feces collection
Description: A single stool sample will be taken (a specific kit will be given to the patient for this) during a consultation for follow-up or hospitalization.~Stool samples will be used to study the composition of the intestinal microbiota and to measure faecal biomarkers.
Study: NCT05449301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation
Description: The participants will receive RAS on regular treadmill for balance and gait improvement. one session per day, 3 session per week for consecutively 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Training
Description: participants will be trained conventionally (bipedal) on regular treadmill. one session per day, 3 session per week for consecutively 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: participants will be trained conventionally (bipedal) on regular treadmill. one session per day, 3 session per week for consecutively 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unilateral Step Training
Description: Patients will be trained on regular treadmill for both paretic and non paretic lower extremity. Single session per day, 3 session per week for consecutively 12 weeks.
Study: NCT05967832

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7T MRI
Description: Patients and healthy volunteers will have a 7T MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7T MRI
Description: Patients and healthy volunteers will have a 7T MRI